Articles from Shift Bioscience

Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to end the morbidity and mortality of aging, today announced the release of new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models1. Using well-calibrated metrics, the study demonstrates that virtual cell models consistently outperform key baselines, providing valuable and actionable biological insights to accelerate target identification pipelines.

Shift Bioscience (Shift), a biotech company using an AI powered virtual cell to fight age-driven diseases, today announced the appointments of Lord David Prior as Chair of the Board and Sir Tony Kouzarides as Scientific Advisor. Bringing significant industry expertise and leadership, Tony and David will provide crucial support to advance Shift’s therapeutic pipeline, helping to foster new industry partnerships and broaden awareness of the Company’s long-term mission to treat disease by targeting underlying cellular aging.

Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Jill and Laurence will guide Shift in building a robust product translation and business development strategy respectively, enabling the Company to capitalize on early momentum and progress its pipeline of novel rejuvenation therapeutics towards clinical development.

Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the establishment of a new North American team and facilities to advance development of the Company’s platform for discovery of rejuvenation gene targets. Based in Toronto, Canada, the team will be led by Lucas Camillo, Head of Machine Learning, with Professor Bo Wang appointed as Senior Advisor. By expanding into this AI hub, the Company gains access to top machine learning talent, enabling it to further strengthen its IP portfolio and develop new capabilities for its virtual cell platform.

Shift Bioscience is a biotech company using generative AI models to understand how activation of different genes can reverse the aging process. This research is a fundamental step forward in designing more effective drugs to treat age-related diseases. Today the company announced that it has raised $16M (£12.5M) in Seed funding, led by BGF, with existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner participating. The investment will be used for the continued development of Shift Bioscience’s artificial intelligence (AI) cell simulation platform, for the identification of genes that can safely rejuvenate cells to combat the effects of age-related illnesses.